SenzaGen signs licensing agreement with Eurofins BioPharma

SenzaGen asserted that the company has signed a global licensing agreement with leading contract research organization Eurofins BioPharma Product Testing Munich to endorse the GARD test to its clients. GARD is a genome-based test with higher accuracy than other available test methods.

Under the terms of the agreement, Eurofins BPT Munich will immediately include GARDskin and the add on test GARDpotency as a leading diagnostic tool in its chemical safety testing services to clients in the cosmetic, chemical and pharmaceutical industries worldwide.

SenzaGen’s CEO Anki Malmborg Hager said “This new license agreement with such a major and strong partner provides an important stepping stone in the global marketing of GARD and it is also a hallmark of the high quality and relevance of GARD. We are very pleased to sign this important deal, in particular since Eurofins BPT Munich is a leading player in chemical safety testing, with a pronounced mission to contribute to global health and safety.”